Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | ME2 | P23368 | 1/20 | 0.47 |
| ▸ | ME1 | P48163 | 1/20 | 0.47 |
| ▸ | ME3 | Q16798 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | CA6 | P23280 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | CA5A | P35218 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.40 |
| ▸ | LDHA | P00338 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8747621 | 0.94 | GPR35 (0.65) | GPR35POLBME2ME1ME3 | |
| SCHEMBL6350580 | 0.83 | POLB (0.85) | GPR35POLBME2ME1ME3 | |
| SCHEMBL26025326 | 0.80 | GPR35 (0.78) | GPR35POLBME2ME1ME3 | |
| SCHEMBL19202294 | 0.79 | CSNK2A1 (0.52) | GPR35POLBMEN1KMT2ACSNK2A1 | |
| SCHEMBL6010055 | 0.78 | GPR35 (0.67) | GPR35POLBME2ME1ME3 | |
| SCHEMBL6347777 | 0.77 | MEN1 (0.50) | GPR35POLBMEN1KMT2ACSNK2A1 | |
| SCHEMBL13057645 | 0.77 | LDHA (0.54) | GPR35POLBMEN1KMT2ACSNK2A1 | |
| SCHEMBL8747607 | 0.77 | GPR35 (0.61) | GPR35POLBME2ME1ME3 | |
| SCHEMBL6351094 | 0.77 | GPR35 (0.65) | GPR35POLBME2ME1ME3 | |
| SCHEMBL8747627 | 0.77 | GPR35 (0.65) | GPR35POLBME2ME1ME3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9622995-B2 | Treatment of disorders associated with G protein-coupled receptor 35 (GPR35) | Temple University—Of the Commonwealth System of Higher Education (US) | 2017-04-18 | — | — | US | disclosed |
| US-20150265561-A1 | TREATMENT OF DISORDERS ASSOCIATED WITH G PROTEIN-COUPLED RECEPTOR 35 (GPR35) | NATIONAL INSTITUTES OF HEALTH | 2015-09-24 | — | — | US | disclosed |
| US-9040583-B2 | Treatment of disorders associated with G protein-coupled receptor 35 (GPR35) | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2015-05-26 | — | — | US | disclosed |
| US-20120122987-A1 | TREATMENT OF DISORDERS ASSOCIATED WITH G PROTEIN-COUPLED RECEPTOR 35 (GPR35) | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122987-A1 | TREATMENT OF DISORDERS ASSOCIATED WITH G PROTEIN-COUPLED RECEPTOR 35 (GPR35) | GPR35, GPR68, GRM5 | GPR35 1/4885POLB 4617/4885ME2 2603/4885 |
| US-20150265561-A1 | TREATMENT OF DISORDERS ASSOCIATED WITH G PROTEIN-COUPLED RECEPTOR 35 (GPR35) | GPR35, GPR68, GRM5 | GPR35 1/4885POLB 4617/4885ME2 2603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.